Friedreich’s ataxia (FA) is a progressive neurodegenerative disease of children and adults for which there is presently no approved therapy. FA symptoms include neurologic, cardiac, orthopedic, and endocrine dysfunction.
We invite you to join us for a night of scientific discussion bringing together the FA community and national leaders in FA research.
Symposium attendance is free.
5:00 – 6:00pm
Poster Session / Cocktail hour
6:00 – 6:20pm
Welcome and Introduction to the Evening & USF FA Initiative
Dr. Judy Genshaft
Theresa Zesiewicz, MD FAAN, Moderator
Director, USF Ataxia Research Center
6:25 – 6:40pm
Building an FA Research Community and Progress of Research
Jennifer Farmer and Ron Bartek
Executive Director and President, FARA
6:40 – 7:00pm
FA Treatment Pipeline
Sanjay Bidichandani, MBBS, PhD
Chair of Genetics, Professor of Pediatrics, University of Oklahoma College of Medicine & FARA, Board of Directors
7:00 – 7:45pm
Panel Discussion: Engagement with Biotech and Pharma
Colin Meyer, MD, CMO, Reata Pharmaceutical, Inc.
Jeffrey Sherman, MD, CMO, Horizon Pharma, Inc.
Robert De Jager, MD, CMO, Retrotope, Inc.
Jodi A. Cook, PhD, VP Operations, Agilis Biotherapeutics, LLC.
Moderator: Sanjay Bidichandani, MBBS, PhD
7:45 – 8:15pm
Patient Perspectives on FA and Research/Clinical Trial Participation
Participants: Erin O’Neil, Jade Perry, Kendall Harvey, Chris Nercesian
Moderator: Clifton Gooch, MD FAAN, Chair of Neurology, University of South Florida Morsani College of Medicine
8:15 – 8:30pm
Clifton Gooch, MD FAAN